2.50

0.00% 0.00

After Hours: 2.53 0.03 +1.20%

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $2.50, with a volume of 3.35M. It is up +0.00% in the last 24 hours and down -27.54% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Previous Close:

$2.50

Open:

$2.54

24h Volume:

3.35M

Relative Volume:

0.93

Market Cap:

$578.64M

Revenue:

Net Income/Loss:

$-179.82M

P/E Ratio:

-1.8797

EPS:

-1.33

Net Cash Flow:

$-159.16M

1W Performance:

-13.19%

1M Performance:

-27.54%

6M Performance:

+83.82%

1Y Performance:

+138.10%

1-Day Range:

$2.41

$2.61

1-Week Range:

$2.35

$2.9699

52-Week Range:

$0.76

$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1115)

Industry

Biotechnology (621)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

145

Twitter

@GossamerBio

Next Earnings Date

2024-11-07

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	2.50	578.64M	0	-179.82M	-159.16M	-1.33
VRTX Vertex Pharmaceuticals Inc	463.86	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	796.55	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	398.29	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	788.49	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.97	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-10-25	Upgrade	UBS	Neutral → Buy
Jul-14-25	Initiated	Scotiabank	Sector Outperform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

Jan 09, 2026

What is the fair value of Gossamer Bio Inc. stock nowTrade Exit Summary & Smart Investment Allocation Tips - ulpravda.ru

Jan 09, 2026

Jan 08, 2026

Is Gossamer Bio Inc. stock trading at a premium valuation2025 Winners & Losers & High Accuracy Investment Signals - ulpravda.ru

Jan 08, 2026